StockData
Eloxx Pharmaceuticals, Inc. logo

Eloxx Pharmaceuticals, Inc. (ELOX) stock

ELOXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$11.74−1.01 (-7.92%)

Close on Nov 17, 2026Market cap $79.70MP/E –Yield –

Eloxx Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Eloxx Pharmaceuticals's R&D Expenses for the twelve months ending Dec 31, 2023 was $8.60M, down 63.8% year over year. For fiscal 2025 it was $3.06M, down 14.6% from the year before. Over ten years it grew -0.9% a year on average. The highest annual figure on record is $26.35M in fiscal 2019.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$3.06M-14.6%
FY2024Dec 31, 2024$3.58M-58.4%
FY2023Dec 31, 2023$8.60M-63.8%
FY2022Dec 31, 2022$23.73M+3.6%
FY2021Dec 31, 2021$22.90M+56.9%
FY2020Dec 31, 2020$14.59M-44.6%
FY2019Dec 31, 2019$26.35M+28.6%
FY2018Dec 31, 2018$20.49M+838.6%
FY2016Jun 30, 2016$2.18M-52.2%
FY2015Jun 30, 2015$4.57M+36.8%
FY2014Jun 30, 2014$3.34M+60.0%
FY2013Jun 30, 2013$2.09M-18.7%
FY2012Jun 30, 2012$2.57M-31.0%
FY2011Jun 30, 2011$3.72M+41.1%
FY2010Jun 30, 2010$2.64M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026$2.84M+86.6%
Q1 FY2026CQ1 2026Mar 31, 2026$1.66M+32.7%
Q2 FY2025CQ2 2025Jun 30, 2025$898.00K-61.6%
Q1 FY2025CQ1 2025Mar 31, 2025$510.00K-85.4%
Q4 FY2023CQ4 2023Dec 31, 2023$1.52M-53.8%
Q3 FY2023CQ3 2023Sep 30, 2023$1.25M-74.4%
Q2 FY2023CQ2 2023Jun 30, 2023$2.34M-69.4%
Q1 FY2023CQ1 2023Mar 31, 2023$3.49M-55.8%
Q4 FY2022CQ4 2022Dec 31, 2022$3.30M-58.3%
Q3 FY2022CQ3 2022Sep 30, 2022$4.88M-6.3%
Q2 FY2022CQ2 2022Jun 30, 2022$7.65M+34.1%
Q1 FY2022CQ1 2022Mar 31, 2022$7.90M+93.9%
Q4 FY2021CQ4 2021Dec 31, 2021$7.91M+194.1%
Q3 FY2021CQ3 2021Sep 30, 2021$5.21M+53.2%
Q2 FY2021CQ2 2021Jun 30, 2021$5.70M+54.2%
Q1 FY2021CQ1 2021Mar 31, 2021$4.07M-14.6%
Q4 FY2020CQ4 2020Dec 31, 2020$2.69M-56.5%
Q3 FY2020CQ3 2020Sep 30, 2020$3.40M-50.0%
Q2 FY2020CQ2 2020Jun 30, 2020$3.70M-49.6%
Q1 FY2020CQ1 2020Mar 31, 2020$4.77M-20.8%
Q4 FY2019CQ4 2019Dec 31, 2019$6.19M-5.2%
Q3 FY2019CQ3 2019Sep 30, 2019$6.80M+25.6%
Q2 FY2019CQ2 2019Jun 30, 2019$7.34M+76.9%
Q1 FY2019CQ1 2019Mar 31, 2019$6.02M+37.0%
Q4 FY2018CQ4 2018Dec 31, 2018$6.53M+1490.9%
Q3 FY2018CQ3 2018Sep 30, 2018$5.42M+839.4%
Q2 FY2018CQ2 2018Jun 30, 2018$4.15M+598.1%
Q1 FY2018CQ1 2018Mar 31, 2018$4.39M+630.4%
Q4 FY2016CQ2 2016Jun 30, 2016$410.46K-51.2%
Q3 FY2016CQ1 2016Mar 31, 2016$576.44K+145.0%
Q2 FY2016CQ4 2015Dec 31, 2015$594.50K-56.7%
Q1 FY2016CQ3 2015Sep 30, 2015$601.58K-71.6%
Q4 FY2015CQ2 2015Jun 30, 2015$841.09K+1.3%
Q3 FY2015CQ1 2015Mar 31, 2015$235.26K-75.7%
Q2 FY2015CQ4 2014Dec 31, 2014$1.37M–
Q1 FY2015CQ3 2014Sep 30, 2014$2.12M–
Q4 FY2014CQ2 2014Jun 30, 2014$830.59K–
Q3 FY2014CQ1 2014Mar 31, 2014$966.34K–

More Eloxx Pharmaceuticals figures

See a number that looks wrong?